These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27888673)

  • 21. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
    Iberer F; Tscheliessnigg KH; Halwachs G; Auer T; Wasler A; Petutschnigg B; Müller H; Freigassner M; Allmayr T; Hipmair G
    Wien Klin Wochenschr; 1995; 107(23):718-22. PubMed ID: 8560893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study.
    Gerna G; Baldanti F; Torsellini M; Minoli L; Viganò M; Oggionnis T; Rampino T; Castiglioni B; Goglio A; Colledan M; Mammana C; Nozza F; Daniele L;
    Antivir Ther; 2007; 12(1):63-72. PubMed ID: 17503749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. "pp65 antigenemia and real time polymerase chain reaction (PCR) based-study to determine the prevalence of human cytomegalovirus (HCMV) in kidney donors and recipients with follow-up studies".
    Madhavan HN; Samson MY; Ishwarya M; Vijayakumar R; Jambulingam M
    Virol J; 2010 Nov; 7():322. PubMed ID: 21080922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation.
    Platzbecker U; Bandt D; Thiede C; Helwig A; Freiberg-Richter J; Schuler U; Plettig R; Geissler G; Rethwilm A; Ehninger G; Bornhäuser M
    Transplantation; 2001 Apr; 71(7):880-5. PubMed ID: 11349720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A universal preemptive therapy for cytomegalovirus infections in children after live-donor liver transplantation.
    Saitoh A; Sakamoto S; Fukuda A; Shigeta T; Kakiuchi T; Kamiyama S; Katsuta T; Shoji K; Ogimi C; Kasahara M
    Transplantation; 2011 Oct; 92(8):930-5. PubMed ID: 21941226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation.
    Gerna G; Lilleri D; Callegaro A; Goglio A; Cortese S; Stroppa P; Torre G
    Transplantation; 2008 Jul; 86(1):163-6. PubMed ID: 18622294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation.
    Rayes N; Seehofer D; Schmidt CA; Oettle H; Müller AR; Steinmüller T; Settmacher U; Bechstein WO; Neuhaus P
    Transplantation; 2001 Sep; 72(5):881-5. PubMed ID: 11571454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preemptive therapy for the prevention of cytomegalovirus disease in renal transplant recipients: our preliminary experience.
    Paudice N; Mehmetaj A; Zanazzi M; Moscarelli L; Piperno R; Di Maria L; Bertoni E; Salvadori M
    Transplant Proc; 2009 May; 41(4):1204-6. PubMed ID: 19460517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial.
    Gerna G; Lilleri D; Baldanti F; Torsellini M; Giorgiani G; Zecca M; De Stefano P; Middeldorp J; Locatelli F; Revello MG
    Blood; 2003 Jun; 101(12):5053-60. PubMed ID: 12586622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Shell-vial culture and pp65 antigenemia assay in the detection of cytomegalovirus in the first blood sample of renal transplant recipients.
    Reina J; Fernandez-Baca V; Saurina J; Blanco I; Munar M
    J Med Virol; 1998 Jul; 55(3):240-2. PubMed ID: 9624613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention and treatment of cytomegalovirus infection in organ transplant recipients.
    Kusne S; Shapiro R; Fung J
    Transpl Infect Dis; 1999 Sep; 1(3):187-203. PubMed ID: 11428989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients. Longitudinal follow-up of CMV pp65 antigenemia assay.
    Yang CW; Kim YO; Kim YS; Kim SY; Moon IS; Ahn HJ; Koh YB; Bang BK
    Am J Nephrol; 1998; 18(5):373-8. PubMed ID: 9730559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum polymerase chain reaction for cytomegalovirus DNA for monitoring ganciclovir treatment in AIDS patients.
    Marenzi R; Cinque P; Ceresa D; Racca S; Lillo F; Lazzarin A
    Scand J Infect Dis; 1996; 28(4):347-51. PubMed ID: 8893396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture.
    Boeckh M; Gallez-Hawkins GM; Myerson D; Zaia JA; Bowden RA
    Transplantation; 1997 Jul; 64(1):108-13. PubMed ID: 9233710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring of human cytomegalovirus infections in heart transplant recipients by pp65 antigenemia.
    Sénéchal M; Dorent R; du Montcel ST; Fillet AM; Ghossoub JJ; Dubois M; Pavie A; Gandjbakhch I
    Clin Transplant; 2003 Oct; 17(5):423-7. PubMed ID: 14703924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between pp65 antigenemia levels and real-time quantitative DNA PCR for Human Cytomegalovirus (HCMV) management in immunocompromised patients.
    Cariani E; Pollara CP; Valloncini B; Perandin F; Bonfanti C; Manca N
    BMC Infect Dis; 2007 Nov; 7():138. PubMed ID: 18036216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts.
    Singh N; Wannstedt C; Keyes L; Mayher D; Tickerhoof L; Akoad M; Wagener MM; Cacciarelli TV
    Liver Transpl; 2008 Feb; 14(2):240-4. PubMed ID: 18236404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients.
    Singh N
    Clin Infect Dis; 2001 Mar; 32(5):742-51. PubMed ID: 11229841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A longitudinal prospective study of cytomegalovirus pp65 antigenemia in renal transplant recipients.
    Bein G; Bitsch A; Hoyer J; Steinhoff J; Fricke L; Machnik H; Dennin R; Kirchner H
    Transpl Int; 1993; 6(4):185-90. PubMed ID: 8394089
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
    Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.